Fulcrum Therapeutics (FULC) Receivables - Other (2020 - 2025)

Fulcrum Therapeutics (FULC) has reported Receivables - Other for 6 consecutive years, with $979000.0 the latest figure, recorded in Q1 2025.

• In Q1 2025, Receivables - Other changed N/A year-over-year to $979000.0; the TTM figure through Mar 2025 stood at $979000.0 (changed N/A YoY), while the FY2024 annual figure was $2.1 million, up 290.32% from the prior year.
• Receivables - Other retreated to $979000.0 in Q1 2025 per FULC's latest filing, from $2.1 million in the prior quarter.
• Across five years, Receivables - Other topped out at $3.7 million in Q3 2024 and bottomed at $99000.0 in Q1 2023.
• Historically, Receivables - Other has averaged $1.1 million across 5 years, with a median of $766500.0 in 2022.
• Annual changes were most pronounced in 2022 — Receivables - Other plunged 90.84% — and 2024, when it jumped 530.34%.
• Fulcrum Therapeutics' Receivables - Other stood at $2.5 million in 2021, then slumped by 90.84% to $229000.0 in 2022, then jumped by 134.5% to $537000.0 in 2023, then surged by 290.32% to $2.1 million in 2024, then slumped by 53.29% to $979000.0 in 2025.
• Business Quant data shows FULC's Receivables - Other at $979000.0 in Q1 2025, $2.1 million in Q4 2024, and $3.7 million in Q3 2024.